肿瘤细胞治疗研究
英文原题：Intratumoral Immunotherapy in Breast Cancer.
Intratumoral Immunotherapy in Breast Cancer.
乳腺癌仍是女性中最常被诊断的癌症，也是导致女性癌症死亡的第二大原因。
乳腺癌仍然是女性中诊断最频繁的癌症，也是癌症死亡的第二大原因。对传统治疗耐药的转移性复发是一个重大挑战，需要开发创新的治疗策略。免疫治疗在癌症治疗中越来越受欢迎，尤其是黑色素瘤、肺癌，以及最近在乳腺癌中。随着对肿瘤微环境以及如何操纵微环境以诱导抗肿瘤免疫反应的更好理解，免疫治疗取得了重大进展。瘤内递送的免疫治疗可用于产生局部免疫反应。本综述全面概述了乳腺癌的瘤内免疫治疗及其引起的肿瘤微环境变化。所讨论的免疫治疗包括溶瘤病毒、核酸、先天免疫激动剂、细菌、CAR-T 细胞和树突状细胞。本综述还评估了使用这些疗法的已完成临床试验。最后，本综述提供了乳腺癌免疫治疗发展的未来展望。
Breast cancer remains the most frequently diagnosed cancer and the second highest cause of cancer death in females. Metastatic recurrence that is resistant to traditional therapies presents a major challenge, necessitating the development of an innovative treatment strategy. Immunotherapy has gained popularity in the treatment of cancer, particularly melanoma, lung cancer, and more recently breast cancer. Major developments in immunotherapy have been made with a better understanding of the tumor microenvironment and how the microenvironment can be manipulated to induce an anti-tumor immune response. Intratumorally delivered immunotherapy can be used to create a local immune response. This review provides a comprehensive overview of intratumoral immunotherapy for breast cancer and its resultant changes in the tumor microenvironment. The discussed immunotherapeutics include oncolytic viruses, nucleic acids, innate immune agonists, bacteria, chimeric antigen receptor T cells, and dendritic cells. The review also evaluates completed clinical trials using these therapies. Lastly, the review offers future perspectives in the development of breast cancer immunotherapy.
MEMBER ACCOUNT
登录成功会直接打开下一页。
